USFDA Approves Sales Of Aurobindo Pharma’s Ulcer Drug In The Market

by Lakshmi Darshini on  August 21, 2015 at 6:56 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The US Food and Drug Administration (USFDA) has approved Aurobindo Pharma to market generic version of Prilosec delayed-release capsules, used to treat ulcer, in the American market.
USFDA Approves Sales Of Aurobindo Pharma’s Ulcer Drug In The Market
USFDA Approves Sales Of Aurobindo Pharma’s Ulcer Drug In The Market

The company has received final approval from the USFDA to manufacture and market Omeprazole delayed-release capsules in the strengths of 10mg, 20mg and 40mg, Aurobindo Pharma said.

The company's approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals' Prilosec capsules, it added. Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults.

According to IMS, the product had an estimated market size of USD 422 million for the twelve months ended June 30.

In a separate statement, the company said it has received approval from the USFDA to market generic version of Hoffmann-La Roche's Boniva injection in the American market. The company's Ibandronate Sodium injection is indicated for the treatment of osteoporosis in postmenopausal women.

Source: PTI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Indigestion Digestive Tract Ulcers Symptom Evaluation 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...